The US government has allocated $176 million to Moderna (MRNA.US) to advance the development of its bird flu vaccine.
Moderna stated that the funding from the US Biomedical Advanced Research and Development Authority will be used to complete late-stage development and testing of its mRNA-based H5N1 bird flu vaccine before the COVID-19 pandemic.
Since March of this year, concerns about the outbreak of H5N1 virus in dairy cows in several states in the United States and the infection of three dairy workers have been increasing in the market.